Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. RESP HEAL
  6. News
  7. Press Releases
    RAP   AU000000RAP5

RESP HEAL

(RAP)
Delayed Australian Stock Exchange  -  02:10 2022-09-15 am EDT
0.2050 AUD   -2.38%
09/15Pfizer Australia Holdings Pty Limited completed the acquisition of ResApp Health Limited.
CI
09/07ResApp Health Secures Shareholder Approval for Takeover Scheme
MT
08/29ResApp Health Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
SummaryQuotesChartsNewsRatingsCompanyFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds
Communiqués de presse de la société RESP HEAL
08/06Resapp Health : Pfizer raises scheme consideration to A$0.208 per share
PU
07/22Resapp Health : Study shows efficacy of ResAppDx use with masks
PU
07/20Resapp Health : Clarification - Scheme Booklet registered with ASIC
PU
07/17Resapp Health : Scheme Booklet registered with ASIC
PU
07/05Resapp Health : Cough detection patent granted in Australia and Japan
PU
07/05Resapp Health : receives FDA 510(k) clearance for SleepCheckRx
PU
06/16Resapp Health : Application for quotation of securities - RAP
PU
06/13Resapp Health : Increased Scheme Consideration from Pfizer
PU
04/25Resapp Health : Quarterly Activities Report and Appendix 4C
PU
04/10Resapp Health : Proposed Acquisition of ResApp Health by Pfizer
PU
04/01Resapp Health : Dartford and Gravesham NHS Trust to pilot ResAppDx
PU
03/24Kairos Minerals Ltd - Board Update
AQ
03/21Resapp Health : COVID-19 Investor Presentation
PU
03/21Resapp Health : announces positive results for a new novel smartphone-based COVID-19 scree..
PU
02/15Resapp Health : Health Teams to launch ResAppDx on aged care telehealth platform
PU
02/02Resapp Health : Cough analysis patent granted in China
PU
01/26Resapp Health : Further international appointments to COVID-19 Scientific Advisory Board
PU
01/24Resapp Health : ResAppDx goes live with Doctors on Demand in Australia
PU
01/19Resapp Health : Binding LOI signed with Homify to launch ResAppDx in the Philippines
PU
01/16Resapp Health : New publication highlights use of ResAppDx in a COVID-19 fever clinic
PU
01/13Resapp Health : Notification regarding unquoted securities - RAP
PU
2021Resapp Health : Distribution agreement with Sanrai International for emerging markets
PU
2021Resapp Health : receives $818,826 in R&D tax incentive refund
PU
2021Resapp Health : Establishes COVID-19 Scientific Advisory Board
PU
2021Resapp Health : receives world's first regulatory approvals for cough counter smartphone a..
PU
2021Resapp Health : completes COVID-19 study recruitment in India
PU
2021Resapp Health : New publication highlights challenges of diagnosing acute respiratory dise..
PU
2021Resapp Health : secures contract with global pharmaceutical company
PU
2021Resapp Health : Partnership with Carepath for passive in-home monitoring of COPD patients
PU
2021Resapp Health : IRB approval for US COVID-19 study modification
PU
2021Resapp Health : COVID-19 Clinical Studies Update
PU
2021Resapp Health : announces FDA 510(k) submission for SleepCheckRx
PU
2021Resapp Health : First patients recruited in COVID-19 clinical study in India
PU
2021Resapp Health : receives Advanced and Overseas R&D finding
PU
2021Resapp Health : ResAppDx receives regulatory approval in Indonesia
PU
2021Resapp Health : Alodokter to launch ResAppDx in Indonesia
PU
2021Resapp Health : Medgate enters licence agreement with ResApp Health
PU
2021Resapp Health : Commercial agreement with Doctors on Demand in Australia
PU
2021Resapp Health : Medgate extends European ResAppDx trial
PU
2021Resapp Health : Agreement secured with Ilara Health to sell ResAppDx in Kenya
PU
2021Resapp Health : secures firm commitments to raise $5.5 million
PU
2021Resapp Health : TGA clearance achieved for wearable
PU
2021Resapp Health : Morgans rates RAP as Add
AQ
2020Resapp Health : Morgans rates RAP as Add
AQ
2019Resapp Health : 2019 Letter to Shareholders
PU
2017Resapp Health : Updated Corporate Governance Policies
PU
2017Resapp Health : Update on Field Evaluation by Médecins Sans Frontières/Doctors Without Bor..
PU
2017Resapp Health : Update on Field Evaluation by Medecins Sans Frontieres
PU
2017Resapp Health : SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
PU
2017Resapp Health : Appendix 4E - Preliminary Final Report
PU
2017Resapp Health : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
2017Resapp Health : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
2017Resapp Health : Receives R&D Tax Incentive Cash Refund for FY16
PU
2017Resapp Health : Reports Preliminary Top-line Results from SMARTCOUGH-C Study for Diagnosis..
PU
2017Resapp Health : Change of Director's Interest Notice
PU
2017Resapp Health : Investor Conference Call
PU
2017Resapp Health : Appendix 4C - Quarterly Jun 2017
PU
2017Resapp Health : Investor Presentation
PU
2017Resapp Health : Morgans Initiates Research Coverage
PU
2017Resapp Health : Release of Restricted Securities
PU
2017Resapp Health : Announces Completion of Enrolment in SMARTCOUGH-C Study
PU
2017Resapp Health : Completion of Enrolment in SMARTCOUGH-C Study
PU
2017Resapp Health : Presentation at ASX Spotlight Investor Conference
PU
2017Resapp Health : Provides SMARTCOUGH-C May Study Update
PU
2017Resapp Health : ResAppDx to be Formally Evaluated by Médecins Sans Frontières/Doctors With..
PU
2017Resapp Health : ResAppDx to be Formally Evaluated by Doctors Without Borders
PU
2017Resapp Health : Extension of CEO and Managing Director's Contract
PU
2017Resapp Health : Licenses Additional Pneumonia Diagnostic Tool from UniQuest
PU
2017Resapp Health : Appendix 4C - Quarterly Mar 2017
PU
2017Lnk : Change of Perth Address for Shareholder Purposes
PU
2017Resapp Health : Extends SMARTCOUGH-C Study
PU
2017Resapp Health : to Present at Upcoming Conferences in March
PU
2017Resapp Health : Appendix 3B
PU
2017Resapp Health : Appendix 4C - Quarterly Dec 2016
PU
2017Resapp Health : Announces Expanded Research Collaboration with MGH
PU
1  2Next